Deutsche Bank Maintains Buy on Spyre Therapeutics, Lowers Price Target to $127

Benzinga Newsdesk www.benzinga.com Negative 57.5%

Neg 57.5% Neu 0% Pos 0%

Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the price target from $135 to $127.